BioSpace News Archive

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2022 financial results and business highlights.

Aytu BioPharma, Inc. announced financial and operational results for the quarter ended December 31, 2022.

Hyperfine, Inc., the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable MRI system, announced CE Marking for the product.

Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that David Fischel, Chairman and CEO, will participate in the Cowen 43rd Annual Health Care Conference.

Neuronetics, Inc. announced their participation as a Silver Sponsor at the 5th International Brain Stimulation Conference in Lisbon, Portugal February 19-22, 2023, where Dr. Harold Sackeim, Professor in Psychiatry and Radiology at Columbia University and poster co-author, will showcase NeuroStar® Advanced Therapy’s latest research findings regarding the strong correlation between the number of transcranial magnetic stimulation treatment sessions delivered and depression relief.

Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Lurasidone HCL tablets to its line of generic drugs.

Medical device incubator and technology brokerage firm, Hatch Medical, L.L.C. (www.hatchmedical.com) announced recently that it has been retained by EndoBar Solutions, LLC to broker a strategic transaction related to its robotic embolization system, Lamina™.

Adial Pharmaceuticals, Inc. announced that it has secured meetings with regulatory authorities in the U.S. and Europe to discuss and develop plans for the clinical advancement of AD04 for alcohol use disorder toward potential approvals.

Molecular Designs, LLC, a developer and manufacturer of molecular multiplex pathogen assays, announced the successful completion of a recent ISO 13485:2016 inspection and certification of its Quality Management System.

Eli Lilly and Company (NYSE: LLY) will participate in Cowen’s 43rd Annual Health Care Conference on Monday, March 6, 2023. Mike Mason, executive vice president and president, Lilly Diabetes and Obesity, will participate in a fireside chat at 1:30 p.m., Eastern time.